Summary

Wyndly provides a convenient and affordable way to fix your allergies forever. Wyndly’s doctors train your immune system to ignore its allergy triggers, and their telehealth platform provides 24/7 access to a doctor. Using FDA-approved medicines and telehealth, Wyndly is increasing access to allergy immunotherapy for the 50 million Americans suffering from severe allergies.

Background

Wyndly cofounder Dr. Manan Shah saw that the healthcare system incentivized providing allergy sufferers weekly allergy shots to maximize revenue, even though a more convenient, safer, and affordable treatment existed: oral at-home allergy immunotherapy. Seeing the opportunity for a superior solution for patients, Manan teamed up with his cousin, Aakash, to build a specialty online allergy practice that offered the highest quality care to patients across the country - without asking them to come to an in-person appointment.

Aakash and Manan participated in the Y Combinator Winter 2021 batch, and since graduating have seen exciting revenue growth and patient outcomes. They plan to use this round to fuel growth and double down on new patient outreach efforts.

Why Cashmere Fund Invested:

Allergy care is ripe for disruption:

Because of traditional allergist training and insurance incentives, traditional allergy clinics rely on weekly in-clinic shots to cure patient allergies. This makes it very difficult for busy professionals, children, and rural areas to get the consistent treatments they for the full 3-5 year treatment cycle. Wyndly, however, provides top-care treatment for patients at home, wherever they may move to, without sitting in a waiting room and dealing with needles.

Wyndly offers the highest quality of care available:

When compared to traditional treatments, research published in The Journal of Allergy and Clinical Immunology shows shots and oral drops are equally effective in treating allergies. Even better, because drops administer medication at a lower dose and have a much lower risk of causing anaphylactic shock. When compared to other telehealth clinics providing shots, Wyndly is the only company treating patients for more than 1-2 allergens at a time. This is important because most patients have more than one allergy, and see the fastest relief when being treated for all allergies from the beginning. They are also the only offering available to treat children.

Founder-market-fit:

Manan has reputation and network to build a specialty telehealth company accepted by the broader medical community. Manan is a former physician-in-residence at Maryland Venture Fund, a Section Chair at the American Academy of Otolaryngology, and the president of the CO ENT Society. Instead of being a sub-par medical service meant to circumvent a doctor, Wyndly is positioned to be the specialty clinic that referring physicians rely on to give their own patients the care they need, no matter where they live. In addition, Aakash’s experience in product and finance unlock Wyndly’s strategic approach to scale a profitable business at an exciting pace.

Other Active Investors

Y Combinator, Goodwater Capital, Civilization Ventures, Kevin Mahaffey